April 17 (Reuters) - Hi-Tech Pharmacal Co. Inc. (HITK.O) said the U.S. Food and Drug Administration tentatively approved its Ciclopirox, which is the generic equivalent of Dermik Laboratories' Penlac nail fungus treatment.
Final approval is expected upon expiration of Penlac's patent on Sept. 18, the company said in a statement. (Reporting by Anant Vijay Kala in Bangalore)
© Thomson Reuters 2009 All rights reserved
Reuters.com:
Help and Contact Us |
Advertise With Us |
Mobile |
Newsletters |
RSS
|
Labs |
Journalism Handbook |
Archive |
Site Index |
Video Index
Thomson Reuters Corporate: Copyright | Disclaimer | Privacy | Professional Products | Professional Products Support | About Thomson Reuters | Careers
International Editions: Africa | Arabic | Argentina | Brazil | Canada | China | France | Germany | India | Italy | Japan | Latin America | Mexico | Russia | Spain | United Kingdom | United States
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
